ClinicalTrials.gg

Program

tedizolid phosphate

Also written as “TR-701 FA”, “Tedizolid phosphate” and “TR-701 FA 200 mg”.

Its studies are mostly in Skin Diseases, Bacterial · Bacterial Infections · Gram-Positive Bacterial Infections · Pneumonia · Skin Diseases, Infectious, led by 3 companies.

Furthest: phase 3, since Jul 23, 201027 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck250 open or runningphase 3since Jul 23, 2010Apr 23, 2008none ahead
Bayer10 open or runningphase 3since Oct 18, 2013Oct 18, 2013none ahead
Dong-A ST10 open or runningphase 1since Mar 24, 2014Mar 24, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Apr 23, 2008.

  1. Dec 19, 2011Phase 1 study in Healthy SubjectsMerck · NCT01496677 · 28 enrolled · United States
  2. Jan 24, 2012Phase 2 study in CellulitisMerck · NCT01519778 · 200 enrolled · United States
  3. Feb 21, 2012Phase 1 study in Healthy VolunteersMerck · NCT01539473 · 30 enrolled · United States
  4. Apr 11, 2012Phase 1 study in Healthy SubjectsMerck · NCT01577459 · 18 enrolled · United States
  5. Jun 6, 2012Phase 1 study in Healthy SubjectsMerck · NCT01623401 · 72 enrolled · United States
  6. Oct 18, 2013Bayer's first study: phase 3 study in Skin Diseases, InfectiousNew to BayerBayer · NCT01967225 · 125 enrolled · Japan
  7. Dec 18, 2013Phase 3 study in PneumoniaMerck · NCT02019420 · 726 enrolled
  8. Mar 24, 2014Dong-A ST's first study: phase 1 study in HealthyNew to Dong-A STDong-A ST · NCT02097043 · 31 enrolled · Korea, Republic of
  9. Oct 9, 2014Phase 3 study in Skin Diseases, InfectiousMerck · NCT02276482 · 120 enrolled
  10. Jun 17, 2015Phase 1 study in Skin Diseases, BacterialMerck · NCT02477514 · 18 enrolled
  11. Apr 1, 2016Phase 1 study in Gram-Positive Bacterial InfectionsMerck · NCT02750761 · 32 enrolled
  12. Jun 1, 2017Phase 3 study in Acute Bacterial Skin and Skin Structure InfectionsMerck · NCT03176134 · 100 enrolled · United States, Brazil, Bulgaria and more
  13. Jul 12, 2017Phase 1 study in Gram-Positive InfectionsMerck · NCT03217565 · 47 enrolled · United States, Bulgaria, Colombia and more
  14. Dec 10, 2024Phase 1 study in HealthyMerck · NCT06733688 · 36 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06733688Healthy · United States1CompletedMerckApr 15, 202236
NCT03217565Gram-Positive Infections · United States, Bulgaria, Colombia and more1CompletedMerckMar 18, 202347
NCT03176134Acute Bacterial Skin and Skin Structure Infections · United States, Brazil, Bulgaria and more3CompletedMerckJul 6, 2023100
NCT02750761Gram-Positive Bacterial Infections1CompletedMerckDec 16, 201832
NCT02477514Skin Diseases, Bacterial1CompletedMerckAug 201518
NCT02276482Skin Diseases, Infectious3CompletedMerckSep 17, 2018120
NCT02097043Healthy · Korea, Republic of1CompletedDong-A STMay 201431
NCT02019420Pneumonia3CompletedMerckJun 22, 2018726
NCT01967225Skin Diseases, Infectious · Japan3CompletedBayerOct 28, 2016125
NCT01623401Healthy Subjects · United States1CompletedMerckAug 24, 201272
NCT01577459Healthy Subjects · United States1CompletedMerckJun 15, 201218
NCT01539473Healthy Volunteers · United States1CompletedMerckMay 201230
NCT01519778Cellulitis · United States2CompletedMerckAug 27, 2012200
NCT01496677Healthy Subjects · United States1CompletedMerckFeb 28, 201228
NCT01461460Healthy Volunteer · United States1CompletedMerckDec 23, 201148
NCT01452828Renal Insufficiency · United States1CompletedMerckMar 201224
NCT01421511Skin and Subcutaneous Tissue Bacterial Infections · United States, Argentina, Australia and more3CompletedMerckJan 10, 2013666
NCT01431833Hepatic Impairment · United States1CompletedMerckMay 201232
NCT01271998Bacterial Infections · United States1CompletedMerckJan 3, 201120
NCT01170221Skin and Subcutaneous Tissue Bacterial Infections · United States, Argentina, Brazil and more3CompletedMerckSep 30, 2011667
NCT01156077Bacterial Infections1CompletedMerckSep 24, 201120
NCT00983255Bacterial Infections · United States1CompletedMerckJan 201090
NCT00876655Healthy · United States1CompletedMerckMar 200912
NCT00761215Skin Diseases, Infectious · United States2CompletedMerckFeb 24, 2009192
NCT00671814Healthy Subjects · United States1CompletedMerckJun 6, 200880
NCT00671359Healthy · United States1CompletedMerckMay 15, 200812
NCT00666601Healthy · United States1CompletedMerckAug 12, 200815

How it is read

Names in the registry

  • “TR-701 FA”, 9 entries
  • “Tedizolid phosphate”, 2 entries
  • “TR-701 FA 200 mg”, 2 entries
  • “IV Tedizolid Phosphate”, 1 entry
  • “Tedizolid Phosphate Oral Formulation 1 (Reference)”, 1 entry

Codes read as this program: TR701.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.